Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning. Lee PC, Li PY, Lee CY, Lin SR, et al. BMC Cancer 2025;25:1641.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lee PC, Li PY, Lee CY, Lin SR, et al. Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning. BMC Cancer 2025;25:1641.
PMID: 41136986